{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:11:52Z","timestamp":1780319512483,"version":"3.54.1"},"reference-count":170,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Myeloid malignancies encompass a heterogeneous group of haematological disorders, primarily including myelodysplastic syndromes (MDSs) and myeloproliferative neoplasms (MPNs). MDS is characterised by defective myeloid cell maturation, while MPNs involve the pathological overproduction of myeloid lineage cells. In the absence of timely diagnosis and effective clinical intervention, both entities carry a substantial risk of progression to acute myeloid leukaemia (AML). Although allogeneic haematopoietic stem cell transplantation remains the only potentially curative therapy, its application is frequently constrained by patient-related factors such as advanced age and comorbid conditions. While currently, hypomethylating agent therapy (azacitidine and decitabine) is mainly used in high-risk MDS patients, and ruxolitinib is primarily used in symptomatic primary myelofibrosis (PMF-MPN), their clinical efficacy remains suboptimal. More recently, focus has turned toward the role of the tumour microenvironment (TME) in disease pathogenesis and whether therapeutically targeting the TME, either alone or in combination with conventional therapy, could present a new treatment option. Emerging evidence underscores the significant influence of TME components, particularly macrophages and T cells, in modulating immune responses and shaping the leukaemic niche to either facilitate or hinder malignant progression. In response, a new generation of immune checkpoint inhibitors are being developed to target the TME, including PD-1\/CTLA-4 blockers, macrophage-directed agents including CD47 inhibitors, and T cell-targeting checkpoint inhibitors such as TIM-1 and LAG-3. This review will describe the functional role of key TME constituents in the progression of myeloid malignancies and explore the current landscape and future potential of advanced cellular and molecular immunotherapies in the treatment of these disorders.<\/jats:p>","DOI":"10.3390\/cancers18111808","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:19:42Z","timestamp":1780316382000},"page":"1808","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Myeloid Malignancies Beyond the Cell: Targeting the Tumour Microenvironment with Next-Generation Immunotherapies"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9687-1843","authenticated-orcid":false,"given":"Niloofar","family":"Amirian","sequence":"first","affiliation":[{"name":"School of Natural Sciences, College of Health & Science, University of Lincoln, Brayford Pool, Lincoln LN6 7TS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Squires","sequence":"additional","affiliation":[{"name":"School of Natural Sciences, College of Health & Science, University of Lincoln, Brayford Pool, Lincoln LN6 7TS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2964-3487","authenticated-orcid":false,"given":"Lauretta","family":"Azanabor","sequence":"additional","affiliation":[{"name":"School of Natural Sciences, College of Health & Science, University of Lincoln, Brayford Pool, Lincoln LN6 7TS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire L.","family":"Walker","sequence":"additional","affiliation":[{"name":"School of Natural Sciences, College of Health & Science, University of Lincoln, Brayford Pool, Lincoln LN6 7TS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3154-3510","authenticated-orcid":false,"given":"Matthew J.","family":"Simmonds","sequence":"additional","affiliation":[{"name":"School of Natural Sciences, College of Health & Science, University of Lincoln, Brayford Pool, Lincoln LN6 7TS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0598-1816","authenticated-orcid":false,"given":"Ciro","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"School of Natural Sciences, College of Health & Science, University of Lincoln, Brayford Pool, Lincoln LN6 7TS, UK"},{"name":"United Lincolnshire Teaching Hospitals, NHS Trust, Lincoln LN2 5QY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"ref_1","first-page":"811","article-title":"Myeloid malignancies and the microenvironment","volume":"129","author":"Korn","year":"2017","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","article-title":"Incidence, survival and prevalence of myeloid malignancies in Europe","volume":"48","author":"Visser","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Grabek, J., Straube, J., Bywater, M., and Lane, S.W. (2020). MPN: The molecular drivers of disease initiation, progression and transformation and their effect on treatment. Cells, 9.","DOI":"10.3390\/cells9081901"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2022.14578","article-title":"Diagnosis and treatment of myelodysplastic syndromes: A review","volume":"328","author":"Sekeres","year":"2022","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: A comprehensive review and 2016 update","volume":"6","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.leukres.2012.08.008","article-title":"The classification of MDS: From FAB to WHO and beyond","volume":"36","author":"Vardiman","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Baumeister, J., Chatain, N., Sofias, A.M., Lammers, T., and Koschmieder, S. (2021). Progression of myeloproliferative neoplasms (MPN): Diagnostic and therapeutic perspectives. Cells, 10.","DOI":"10.3390\/cells10123551"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.hoc.2020.12.001","article-title":"Overview of MPNs: History, Pathogenesis, Diagnostic Criteria, and Complications","volume":"35","author":"Tremblay","year":"2021","journal-title":"Hematol.\/Oncol. Clin. N. Am."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1101\/gad.276568.115","article-title":"Role of TET enzymes in DNA methylation, development, and cancer","volume":"30","author":"Rasmussen","year":"2016","journal-title":"Genes Dev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s12185-023-03586-y","article-title":"Epigenetic regulation by ASXL1 in myeloid malignancies","volume":"117","author":"Yang","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_12","first-page":"61","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","article-title":"AML treatment: Conventional chemotherapy and emerging novel agents","volume":"45","author":"Forsberg","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-020-0296-3","article-title":"Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia","volume":"10","author":"Schmaelter","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/ijc.35125","article-title":"Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: A multicenter study from China","volume":"155","author":"Dou","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_16","first-page":"2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_17","first-page":"103409","article-title":"Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytog\u00e9n\u00e9tique h\u00e9matologique (GFCH)","volume":"71","author":"Auger","year":"2023","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"873.e1","DOI":"10.1016\/j.jtct.2021.05.016","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis\u2014A systematic review and meta-analysis","volume":"27","author":"Bewersdorf","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/ejh.13353","article-title":"Allogeneic stem cell transplant in myelodysplastic syndrome-factors impacting survival","volume":"104","author":"Prem","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s11864-022-00965-1","article-title":"New approaches to myelodysplastic syndrome treatment","volume":"23","author":"Bazinet","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.bbmt.2017.03.020","article-title":"Allogeneic hematopoietic stem cell transplantation is underutilized in older patients with myelodysplastic syndromes","volume":"23","author":"Getta","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: Mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2018.05.004","article-title":"Outcomes and predictors of survival in blast phase myeloproliferative neoplasms","volume":"70","author":"Lancman","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Nasillo, V., Riva, G., Paolini, A., Forghieri, F., Roncati, L., Lusenti, B., Maccaferri, M., Messerotti, A., Pioli, V., and Gilioli, A. (2021). Inflammatory microenvironment and specific T cells in myeloproliferative neoplasms: Immunopathogenesis and novel immunotherapies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041906"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kouroukli, O., Symeonidis, A., Foukas, P., Maragkou, M.-K., and Kourea, E.P. (2022). Bone marrow immune microenvironment in myelodysplastic syndromes. Cancers, 14.","DOI":"10.3390\/cancers14225656"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.cell.2023.01.038","article-title":"What is cancer metabolism?","volume":"186","author":"Finley","year":"2023","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12272-019-01185-2","article-title":"Warburg effect and its role in tumourigenesis","volume":"42","author":"Lebelo","year":"2019","journal-title":"Arch. Pharmacal Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12032-024-02575-3","article-title":"Metabolic dysregulation in myelodysplastic neoplasm: Impact on pathogenesis and potential therapeutic targets","volume":"42","author":"Zhou","year":"2024","journal-title":"Med. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: Role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Balaian, E., Wobus, M., Bornh\u00e4user, M., Chavakis, T., and Sockel, K. (2021). Myelodysplastic syndromes and metabolism. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011250"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/leu.2011.225","article-title":"The JAK2V617F oncogene requires expression of inducible phosphofructokinase\/fructose-bisphosphatase 3 for cell growth and increased metabolic activity","volume":"26","author":"Reddy","year":"2012","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1158\/2159-8290.CD-19-0152","article-title":"Loss of EZH2 reprograms BCAA metabolism to drive leukemic transformation","volume":"9","author":"Gu","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1126\/science.1179689","article-title":"Regulation of cellular metabolism by protein lysine acetylation","volume":"327","author":"Zhao","year":"2010","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"20406207231183330","DOI":"10.1177\/20406207231183330","article-title":"Immune dysregulation and potential targeted therapy in myelodysplastic syndrome","volume":"14","author":"Zhang","year":"2023","journal-title":"Ther. Adv. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Venney, D., Mohd-Sarip, A., and Mills, K.I. (2021). The impact of epigenetic modifications in myeloid malignancies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22095013"},{"key":"ref_36","first-page":"1586","article-title":"Stem and progenitor cell alterations in myelodysplastic syndromes","volume":"129","author":"Shastri","year":"2017","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Barakos, G.P., and Hatzimichael, E. (2022). Microenvironmental features driving immune evasion in myelodysplastic syndromes and acute myeloid leukemia. Diseases, 10.","DOI":"10.3390\/diseases10020033"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/hematology.2022000350","article-title":"Targeting inflammation in lower-risk MDS","volume":"2022","author":"Verma","year":"2022","journal-title":"Hematology"},{"key":"ref_39","first-page":"2960","article-title":"The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype","volume":"128","author":"Basiorka","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Lynch, O.F., and Calvi, L.M. (2022). Immune dysfunction, cytokine disruption, and stromal changes in myelodysplastic syndrome: A review. Cells, 11.","DOI":"10.3390\/cells11030580"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e15844","DOI":"10.1097\/MD.0000000000015844","article-title":"The inflammatory cytokine profile of myelodysplastic syndromes: A meta-analysis","volume":"98","author":"Shi","year":"2019","journal-title":"Medicine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"106341","DOI":"10.1016\/j.isci.2023.106341","article-title":"Temporal dynamics of TNF-mediated changes in hematopoietic stem cell function and recovery","volume":"26","author":"Nilsson","year":"2023","journal-title":"Iscience"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1080\/10428194.2023.2232492","article-title":"Role of IL8 in myeloid malignancies","volume":"64","author":"Ramachandra","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Camacho, V., Kuznetsova, V., and Welner, R.S. (2021). Inflammatory cytokines shape an altered immune response during myeloid malignancies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.772408"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Huang, B., Lang, X., and Li, X. (2022). The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1023177"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/cdd.2014.85","article-title":"Interleukin-17 enhances immunosuppression by mesenchymal stem cells","volume":"21","author":"Han","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s13287-025-04595-w","article-title":"The interrelationship between interleukin-17 A and the immunomodulation of mesenchymal stromal cells","volume":"16","author":"Ma","year":"2025","journal-title":"Stem Cell Res. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"104999","DOI":"10.1016\/j.critrevonc.2025.104999","article-title":"The central role of IL-17 in cancer stemness and immune evasion: A novel axis for overcoming immune checkpoint inhibitor resistance","volume":"217","author":"Wang","year":"2025","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.jid.5700001","article-title":"Cytotoxic T cells","volume":"126","author":"Andersen","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00262-016-1865-y","article-title":"Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes","volume":"65","author":"Sand","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.autrev.2008.03.001","article-title":"Mechanisms of T regulatory cell function","volume":"7","author":"Askenasy","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"ref_52","first-page":"847","article-title":"CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)","volume":"110","author":"Kordasti","year":"2007","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood.2023023166","article-title":"T-cell dysfunctions in myelodysplastic syndromes","volume":"143","author":"Colla","year":"2024","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3324\/haematol.2012.074823","article-title":"The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome","volume":"98","author":"Costantini","year":"2013","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semcdb.2016.08.009","article-title":"Role of bone marrow macrophages in controlling homeostasis and repair in bone and bone marrow niches","volume":"61","author":"Kaur","year":"2017","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Cencini, E., Fabbri, A., Sicuranza, A., Gozzetti, A., and Bocchia, M. (2021). The role of tumor-associated macrophages in hematologic malignancies. Cancers, 13.","DOI":"10.3390\/cancers13143597"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000357306","article-title":"In vitro and in vivo repair activities of undifferentiated and classically and alternatively activated macrophages","volume":"81","author":"Lehr","year":"2014","journal-title":"Pathobiology"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Feriotti, C., Loures, F.V., Frank de Ara\u00fajo, E., Costa, T.A.d., and Calich, V.L. (2013). Mannosyl-recognizing receptors induce an M1-like phenotype in macrophages of susceptible mice but an M2-like phenotype in mice resistant to a fungal infection. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054845"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","article-title":"New insights into M1\/M2 macrophages: Key modulators in cancer progression","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-021-00627-y","article-title":"M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"9913382","DOI":"10.1155\/2021\/9913382","article-title":"Abnormal macrophage polarization in patients with myelodysplastic syndrome","volume":"2021","author":"Zhang","year":"2021","journal-title":"Mediat. Inflamm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"112837","DOI":"10.1016\/j.yexcr.2021.112837","article-title":"Characteristics of macrophages from myelodysplastic syndrome microenvironment","volume":"408","author":"Yang","year":"2021","journal-title":"Exp. Cell Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e31129","DOI":"10.1002\/jcp.31129","article-title":"Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes","volume":"239","author":"Xing","year":"2024","journal-title":"J. Cell. Physiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"11795549211035540","DOI":"10.1177\/11795549211035540","article-title":"Targeting MDSC for immune-checkpoint blockade in cancer immunotherapy: Current progress and new prospects","volume":"15","author":"Li","year":"2021","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Wang, J.-C., and Sun, L. (2022). PD-1\/PD-L1, MDSC pathways, and checkpoint inhibitor therapy in Ph (-) myeloproliferative neoplasm: A review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105837"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","article-title":"Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression","volume":"22","author":"Sinha","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e1062208","DOI":"10.1080\/2162402X.2015.1062208","article-title":"Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome","volume":"5","author":"Kittang","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_68","first-page":"5266","article-title":"Monocytic myeloid-derived suppressor cells (Mo-MDSC) are increased but not M1 or M2 TAM macrophages in the bone marrow of patients with BCR-ABL negative myeloid neoplasm (MPN)","volume":"130","author":"Chen","year":"2017","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/bloodadvances.2021005198","article-title":"FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology","volume":"6","author":"Botta","year":"2022","journal-title":"Blood Adv."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Verigou, E., Chatzilygeroudi, T., Lazaris, V., de Lastic, A.-L., and Symeonidis, A. (2024). Immunophenotyping myelodysplastic neoplasms: The role of flow cytometry in the molecular classification era. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1447001"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s11095-024-03761-8","article-title":"Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome","volume":"41","author":"Gandhi","year":"2024","journal-title":"Pharm. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semcancer.2022.03.014","article-title":"Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy","volume":"86","author":"Gaikwad","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/aob-21-3","article-title":"A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy","volume":"7","author":"Peng","year":"2022","journal-title":"Ann. Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: From discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_79","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.leukres.2018.01.014","article-title":"PD-1\/PD-L1 checkpoint in hematological malignancies","volume":"67","author":"Annibali","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.htct.2023.05.002","article-title":"High PD-L1 expression is associated with unfavorable clinical features in myelodysplastic neoplasms","volume":"46","author":"Sampaio","year":"2024","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: A rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"Treppendahl","year":"2015","journal-title":"Oncotarget"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-015-0078-9","article-title":"Pembrolizumab","volume":"3","author":"Khoja","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood.V128.22.345.345","article-title":"Pembrolizumab, a PD-1 inhibitor, in patients with myelodysplastic syndrome (MDS) after failure of hypomethylating agent treatment","volume":"128","author":"Tallman","year":"2016","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjh.17689","article-title":"Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome","volume":"195","author":"Chien","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-3-030-02505-2_4","article-title":"Update on immunotherapy in AML and MDS: Monoclonal antibodies and checkpoint inhibitors paving the road for clinical practice","volume":"995","author":"Masarova","year":"2018","journal-title":"Immunotherapy"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2018-99-116078","article-title":"Results of a phase 2, open-label study of idarubicin (I), cytarabine (A) and nivolumab (Nivo) in patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)","volume":"132","author":"Assi","year":"2018","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood.V128.22.344.344","article-title":"A phase II study evaluating the combination of nivolumab (Nivo) or ipilimumab (Ipi) with azacitidine in Pts with previously treated or untreated myelodysplastic syndromes (MDS)","volume":"128","author":"Daver","year":"2016","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-142003","article-title":"A phase II study of double immune checkpoint inhibitor blockade with nivolumab and ipilimumab with or without azacitidine in patients with myelodysplastic syndrome (MDS)","volume":"136","author":"Morita","year":"2020","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","article-title":"Integrin-associated protein (CD47) and its ligands","volume":"11","author":"Ej","year":"2001","journal-title":"Trends Cell Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","article-title":"Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis","volume":"76","author":"Weiskopf","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","article-title":"Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia","volume":"71","author":"Chao","year":"2011","journal-title":"Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zhao, H.-J., Pa, F., Shi, Y.-C., Luo, X., Ren, R.-R., Peng, L.-H., and Yang, Y.-S. (2018). Prognostic significance of CD47 in human malignancies: A systematic review and meta-analysis. Transl. Cancer Res., 7.","DOI":"10.21037\/tcr.2018.05.31"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1182\/blood-2019-128422","article-title":"Expression of CD47 and CALR in myeloproliferative neoplasms and myelodysplastic syndrome: Potential new therapeutical targets","volume":"134","author":"Boasman","year":"2019","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"63ra94","DOI":"10.1126\/scitranslmed.3001375","article-title":"Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47","volume":"2","author":"Chao","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/bj3440281","article-title":"Calreticulin: One protein, one gene, many functions","volume":"344","author":"Michalak","year":"1999","journal-title":"Biochem. J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"526524","DOI":"10.1155\/2015\/526524","article-title":"Functional roles of calreticulin in cancer biology","volume":"2015","author":"Lu","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2005.08.032","article-title":"Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte","volume":"123","author":"Gardai","year":"2005","journal-title":"Cell"},{"key":"ref_101","first-page":"1070","article-title":"Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies: Therapeutic and prognostic implications in myelodysplastic syndromes and myeloproliferative neoplasms","volume":"111","author":"Boasman","year":"2026","journal-title":"Haematologica"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1182\/blood-2018-99-120170","article-title":"Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia","volume":"132","author":"Feng","year":"2018","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.4238\/2015.May.25.15","article-title":"Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro","volume":"14","author":"Wang","year":"2015","journal-title":"Genet Mol. Res."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., Willingham, S., Howard, M., Prohaska, S., and Volkmer, J. (2015). Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137345"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody\u2013mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_107","first-page":"4890","article-title":"Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy","volume":"118","author":"Chao","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/JCO.2019.37.15_suppl.7009","article-title":"The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results","volume":"37","author":"Sallman","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2019-126271","article-title":"The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: Ongoing phase 1b results","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2020.38.15_suppl.7507","article-title":"Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results","volume":"38","author":"Sallman","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: Final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_112","unstructured":"Gilead Sciences (2026, May 21). Gilead to Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS. Available online: https:\/\/www.gilead.com\/news\/news-details\/2023\/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"TPS7055","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7055","article-title":"Magrolimab+ azacitidine versus azacitidine+ placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study","volume":"39","author":"Daver","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/GO.2023.9.Supplement_1.118","article-title":"Effect of ruxolitinib and magrolimab on calreticulin in myelofibrosis CD34+ cells in vitro: Proof of concept for combination therapy","volume":"9","author":"Rinaldi","year":"2023","journal-title":"JCO Glob. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1021\/acsami.2c19311","article-title":"Elimination of cancer cells in co-culture: Role of different nanocarriers in regulation of CD47 and calreticulin-induced phagocytosis","volume":"15","author":"Hassan","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0021-9258(17)42058-8","article-title":"Rh-related antigen CD47 is the signal-transducer integrin-associated protein","volume":"269","author":"Lindberg","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"614619","DOI":"10.1155\/2013\/614619","article-title":"CD47: A cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease","volume":"2013","author":"Oldenborg","year":"2013","journal-title":"ISRN Hematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12967-023-04710-6","article-title":"Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile","volume":"22","author":"Wang","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-134391","article-title":"A phase I\/IIa study of lemzoparlimab, a monoclonal antibody targeting CD47, in patients with relapsed and\/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): Initial phase I results","volume":"136","author":"Qi","year":"2020","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"S827","DOI":"10.1016\/j.annonc.2022.07.743","article-title":"617O Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical results","volume":"33","author":"Xiao","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_122","first-page":"2111","article-title":"TLR3 agonism augments CD47 inhibition in acute myeloid leukemia","volume":"109","author":"Ramsey","year":"2023","journal-title":"Haematologica"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"TPS7067","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7067","article-title":"Lemzoparlimab (lemzo) with venetoclax (ven) and\/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1538-7445.AM2021-1611","article-title":"A novel anti-human CD47 antibody prodrug as cancer therapeutics to lower on-target side effects","volume":"81","author":"Zhang","year":"2021","journal-title":"Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"22719","DOI":"10.1074\/jbc.273.35.22719","article-title":"High expression of inhibitory receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in macrophages","volume":"273","author":"Veillette","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_126","first-page":"3633","article-title":"Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47","volume":"94","author":"Seiffert","year":"1999","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_127","first-page":"4333","article-title":"Is targeting of CD47-SIRP\u03b1 enough for treating hematopoietic malignancy?","volume":"119","author":"Zhao","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-020-02679-5","article-title":"Tumor-selective blockade of CD47 signaling with a CD47\/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity","volume":"70","author":"Wang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s10238-025-01915-5","article-title":"Clinical outcomes and safety of CD47-targeted immunotherapies across hematologic malignancies: A systematic review of monoclonal antibodies and fusion proteins in combination strategies","volume":"25","author":"Mirza","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/trf.15397","article-title":"The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia","volume":"59","author":"Brierley","year":"2019","journal-title":"Transfusion"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2022-155901","article-title":"A phase 1b study to evaluate safety and efficacy of IBI188 in combination with azacitidine (AZA) as a first-line treatment in subjects with newly diagnosed higher risk myelodysplastic syndrome","volume":"140","author":"Miao","year":"2022","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2023-179099","article-title":"Ak117 (Anti-cd47 monoclonal antibody) in combination with azacitidine for newly diagnosed higher risk myelodysplastic syndrome (Hr-mds): Ak117-103 phase 1b results","volume":"142","author":"Miao","year":"2023","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/blood-2023-180618","article-title":"A phase 1b study evaluating the safety and efficacy of ak117 (anti-CD47 monoclonal antibody) in combination with azacitidine in patients with treatment-na\u00efve acute myeloid leukemia","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1182\/blood-2024-200541","article-title":"Trial in progress: A randomized, double-blind, placebo-controlled, multicenter phase 2 study of AK117\/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (AK117-205)","volume":"144","author":"Zeidan","year":"2024","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1200\/JCO.2020.38.15_suppl.3064","article-title":"Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody","volume":"38","author":"Patnaik","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/blood-2019-125363","article-title":"A phase I study of CC-90002, a monoclonal antibody targeting CD47, in patients with relapsed and\/or refractory (R\/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS): Final results","volume":"134","author":"Zeidan","year":"2019","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood-2021-146547","article-title":"Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with azacitidine: A phase 1\/2 study in patients with myelodysplastic syndrome (ASPEN-02)","volume":"138","author":"Erba","year":"2021","journal-title":"Blood"},{"key":"ref_138","first-page":"9046","article-title":"Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with azacitidine and venetoclax in patients with acute myeloid leukemia (ASPEN-05): Results from phase 1a dose escalation part","volume":"40","author":"Przespolewski","year":"2022","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1200\/JCO.2024.42.16_suppl.6510","article-title":"Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS)","volume":"42","author":"Yang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"107933","DOI":"10.1016\/j.intimp.2021.107933","article-title":"TIM-3: An update on immunotherapy","volume":"99","author":"Zhao","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e23849","DOI":"10.4161\/onci.23849","article-title":"TIM3+ FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer","volume":"2","author":"Sakuishi","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2016.11.003","article-title":"Increased TIM3+ CD8+ T cells in Myelodysplastic Syndrome patients displayed less perforin and granzyme B secretion and higher CD95 expression","volume":"51","author":"Tao","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","article-title":"A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression","volume":"17","author":"Kikushige","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1016\/S2152-2650(20)30728-X","article-title":"AML-190: Anti-TIM-3 antibody MBG453 in combination with hypomethylating agents (HMAs) in patients with high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia: A Phase 1 study","volume":"20","author":"Brunner","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"ltac019","DOI":"10.1093\/immadv\/ltac019","article-title":"Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor","volume":"2","author":"Schwartz","year":"2022","journal-title":"Immunother. Adv."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1073\/pnas.94.11.5744","article-title":"Characterization of the major histocompatibility complex class II binding site on LAG-3 protein","volume":"94","author":"Huard","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG 3 (CD 223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1172\/JCI31184","article-title":"LAG-3 regulates CD8+ T cell accumulation and effector function in murine self-and tumor-tolerance systems","volume":"117","author":"Grosso","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","article-title":"Cutting edge: Molecular analysis of the negative regulatory function of lymphocyte activation gene-3","volume":"169","author":"Workman","year":"2002","journal-title":"J. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1912892","DOI":"10.1080\/2162402X.2021.1912892","article-title":"PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy","volume":"10","author":"Zahm","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Lichtenegger, F.S., Rothe, M., Schnorfeil, F.M., Deiser, K., Krupka, C., Augsberger, C., Schl\u00fcter, M., Neitz, J., and Subklewe, M. (2018). Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00385"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.4049\/jimmunol.0903879","article-title":"LAG-3 expression defines a subset of CD4+ CD25highFoxp3+ regulatory T cells that are expanded at tumor sites","volume":"184","author":"Camisaschi","year":"2010","journal-title":"J. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3324\/haematol.2024.285598","article-title":"Different inflammatory, fibrotic, and immunological signatures between pre-fibrotic and overt primary myelofibrosis","volume":"110","author":"Jung","year":"2024","journal-title":"Haematologica"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2023-182601","article-title":"High Expressions of Checkpoint Receptors in T Cells Subsets of Myelodysplastic Syndromes Patients with TP53 Mutations","volume":"142","author":"Jiang","year":"2023","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.31557\/APJCP.2024.25.5.1777","article-title":"Prognostic effect of CTLA4\/LAG3 Expression by T-Cells Subsets on Acute Myeloid Leukemia Patients","volume":"25","author":"Aref","year":"2024","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"ref_160","first-page":"S198","article-title":"AML-273: The Immune checkpoints CTLA-4 and LAG-3 expression is up-regulated in acute myeloid leukemia","volume":"20","author":"Radwan","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood-2019-129455","article-title":"LAG3 inhibition decreases AML-induced immunosuppression and improves T cell-mediated killing","volume":"134","author":"Abdelhakim","year":"2019","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"154632","DOI":"10.1016\/j.prp.2023.154632","article-title":"New immunotherapeutic approaches for cancer treatment","volume":"248","author":"Kamrani","year":"2023","journal-title":"Pathol. -Res. Pract."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev-immunol-101819-024752","article-title":"Beyond the barrier: Unraveling the mechanisms of immunotherapy resistance","volume":"42","author":"Bell","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Bai, R., Chen, N., Li, L., Du, N., Bai, L., Lv, Z., Tian, H., and Cui, J. (2020). Mechanisms of cancer resistance to immunotherapy. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01290"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Jiao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","article-title":"Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Nat. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1808\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:39:55Z","timestamp":1780317595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":170,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18111808"],"URL":"https:\/\/doi.org\/10.3390\/cancers18111808","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}